Literature DB >> 24607728

Latest developments in anticoagulant drug discovery.

Erasmia Broussalis1, Wallner Anna2, Eugen Trinka3, Sebastian Mutzenbach3, Monika Killer4.   

Abstract

Thromboembolic diseases have increased in number over the past years. Oral anticoagulants impair the formation and progression of thrombotic processes and are therefore of great importance in the treatment of these diseases. Until recently, vitamin K antagonists were used to block the coagulation system. But these agents display a lot of interactions besides their narrow therapeutic range and have potential risk of hemorrhage complications. Therefore, other factors of the coagulation cascade are currently being explored as therapeutic targets for the development of novel anticoagulants. This review will provide an overview of new drugs promising more effectiveness in the treatment of arterial and venous embolism. Furthermore, pharmacodynamics and drug interactions regarding new anticoagulants will be reported.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24607728     DOI: 10.1016/j.drudis.2014.02.011

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  3 in total

Review 1.  Future prospects for contact factors as therapeutic targets.

Authors:  David Gailani
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2014-11-18

Review 2.  Use of novel oral anticoagulants for the treatment of venous thromboembolism and its considerations in Asian patients.

Authors:  Yun-Jeong Lee
Journal:  Ther Clin Risk Manag       Date:  2014-10-07       Impact factor: 2.423

3.  Fragment-Based Lead Generation of 5-Phenyl-1H-pyrazole-3-carboxamide Derivatives as Leads for Potent Factor Xia Inhibitors.

Authors:  Qunchao Wei; Zhichao Zheng; Shijun Zhang; Xuemin Zheng; Fancui Meng; Jing Yuan; Yongnan Xu; Changjiang Huang
Journal:  Molecules       Date:  2018-08-10       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.